Despite ambitions to streamline regulatory review, FDA’s Elsa platform has been prone to hallucinations, prompting internal scrutiny and questions about AI reliability and governance.
Chris Mazzolini
Advertisement
Articles by Chris Mazzolini
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The 10 Most Powerful Study KRIs in RBQM and GCP Issues They Can Prevent
2
ACT Brief: APAC Inspection Findings, RBQM Key Risk Indicators, and Head and Neck Cancer Approval
3
What FDA Inspections Reveal About the Quality of APAC Clinical Trial Sites
4
How China Cut Its Phase III Startup Timeline and What Drove the Change
5